BRUCE Protein, New Marker for Targeted Therapy of Gastric Carcinoma.
OBJECTIVE
Evading apoptosis is one of the major hallmarks of cancer cells. Inhibitors of apoptosis (IAPs) proteins are considered as a most important gene families involved in apoptosis. BRUCE protein, a member of IAPs, is able to quench apoptosis as well as playing role in cell division. Our aim in this study was to analyze BRUCE protein expression in gastric carcinoma (GC) and its correlation with the clinicopathological features.


METHODS
Using immunohistochemistry, 52 GC specimens were studied for BRUCE protein expression. A validated scoring method was applied.


RESULTS
BRUCE protein expression was detected in majority of tumor tissues (98.07 %). A significant correlation between gender and BRUCE expression (p = 0.024) was detected. Indeed, females showed higher level of BRUCE expression than male patients.


CONCLUSIONS
Since specific expression of BRUCE protein was revealed in majority of GC tissues, BRUCE protein may be a useful therapeutic target for cancer therapy. Furthermore, based on the native role of BRUCE protein in inhibition of apoptosis, using this protein in targeted therapy of tumor cells may help to inhibit tumor cells growth and survival leading to rapid elimination of tumor mass.
Cancer Molecular Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Somayeh
S
Salehi
Cancer Molecular Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hossein
AH
Jafarian
Dr Moaven Hospital, Kermanshah University of Medical Sciences, Sahneh, Kermanshah, Iran.
Mehdi
M
Montazer
Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Meysam
M
Moghbeli
Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran. forghanifard@gmail.com.
Mohammad Mahdi
MM
Forghanifard
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000378:metabolism; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods; D009367:Neoplasm Staging; D012737:Sex Factors; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery
D000970:Antineoplastic Agents; C401541:BIRC6 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins
Apoptosis; BRUCE; Gastric carcinoma; IAP; Immunohistochemistry